Announcement on Subsidiary Obtaining Innovative Drug "Drug Clinical Trial Approval Notice"

Chongqing Pharscin Pharmaceutical Co., Ltd.·August 13, 2026·2 pages

✨ AI Summary

Chongqing Huasen Pharmaceutical's subsidiary, Chengdu Huasen Aorui Pharmaceutical, received approval for its ORIC-1327 eye drops for glaucoma and ocular hypertension. This marks the second Class 1.1 new drug clinical trial approval for Aorui, supporting the company's "innovation and imitation" strategy. The company cautions that drug development is uncertain and success is not guaranteed.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002907

Securities Abbreviation: Huasen Pharmaceutical

Announcement No.: 2026-055

Chongqing Huasen Pharmaceutical Co., Ltd.

Announcement on Subsidiary Obtaining Innovative Drug "Drug Clinical Trial Approval Notice"

The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.

Chongqing Huasen Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its holding subsidiary Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (hereinafter referred to as "Huasen Aorui") recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for the Fosun ORIC-1327 eye drops, covering 2 indications and 6 specifications. The relevant situation is announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.